Damora Therapeutics (DMRA) Q2 2026 earnings summary

Executive summary

• Completed acquisition of Pre-Acquisition Damora, focusing on therapies for hematologic malignancies, particularly myeloproliferative neoplasms (MPNs) driven by mutant calreticulin (mutCALR).

• Initiated Phase 1/1b clinical trial for lead asset DMR-001 in ET and MF patients, following health authority approval; presented preclinical data at EHA 2026 showing DMR-001's best-in-class potential.

• Regulatory submissions for DMR-002 planned for H2 2026 and DMR-003 in 2027.

• Raised significant capital through a $295.5M public offering and $29.3M ATM program, strengthening cash position to $540.5M as of June 30, 2026.

• Changed jurisdiction of incorporation from Delaware to Cayman Islands in July 2026.

Financial highlights

• Cash and cash equivalents increased to $540.5M at June 30, 2026, from $257.6M at December 31, 2025.

• Net loss for Q2 2026 was $31.2M, up from $3.4M in Q2 2025; net loss for H1 2026 was $59.0M, up from $6.0M in H1 2025.

• Research and development expenses rose to $25.5M in Q2 2026 (vs. $1.5M in Q2 2025), driven by increased preclinical, clinical, and manufacturing costs.

• General and administrative expenses increased to $9.5M in Q2 2026 (vs. $2.0M in Q2 2025), mainly due to higher personnel and professional fees.

• Other income, net, was $4.1M in Q2 2026, reflecting increased interest income from recent financings.

Outlook and guidance

• Cash runway expected to fund operations into the second half of 2029 based on current estimates.

• Continued negative cash flows projected as R&D investments accelerate; additional financing will be needed for future development and commercialization.

• Plans to expand DMR-001 clinical trial globally and initiate regulatory submissions for DMR-002 and DMR-003 in 2026 and 2027, respectively.

• Two clinical proof-of-concept datasets for DMR-001 anticipated beginning mid-2027.